Massimo Breccia | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
IS THE SURVIVAL OF PATIENTS WITH ESSENTIAL THROMBOCYTEMIA BETTER IN THE LAST DECADE? RETROSPECTIVE ANALYSIS OF DATABASE OF LATIAL GROUP FOR THE STUDY OF NMP, PH NEGATIVE	HAEMATOLOGICA	2017
A population-based study on myelodysplastic syndromes in the Lazio Region (Italy), medical miscoding and 11-year mortality follow-up. The Gruppo Romano-Laziale Mielodisplasie experience of retrospective multicentric registry	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2017
Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.	BRITISH JOURNAL OF HAEMATOLOGY	2017
Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors.	BRITISH JOURNAL OF HAEMATOLOGY	2017
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia	HAEMATOLOGICA	2017
The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials	AMERICAN JOURNAL OF HEMATOLOGY	2017
ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPLICON DEEP SEQUENCING FOR BCR-ABL1 KINASE DOMAIN MUTATION SCREENING: THE 'NEXT-IN-CML' STUDY	HAEMATOLOGICA	2017
DEVELOPMENT AND EXTERNAL VALIDATION OF A NEW PATIENT-CENTERED PROGNOSTIC INDEX FOR PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES	HAEMATOLOGICA	2017
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib	AMERICAN JOURNAL OF HEMATOLOGY	2017
Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia	HEMATOLOGICAL ONCOLOGY	2017
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion	ANNALS OF HEMATOLOGY	2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis	ONCOTARGET	2017
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome	BRITISH JOURNAL OF HAEMATOLOGY	2017
IMPACT OF COMORBIDITIES AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB	HAEMATOLOGICA	2017
Recovering from chronic myeloid leukemia: the patients' perspective seen through the lens of narrative medicine	QUALITY OF LIFE RESEARCH	2017
IMPACT OF BCR-ABL1 TRANSCRIPT TYPE IN CHRONIC MYELOID LEUKEMIA TREATED FRONTLINE WITH NILOTINIB	HAEMATOLOGICA	2017
Second line small molecule therapy options for treating chronic myeloid leukemia	EXPERT OPINION ON PHARMACOTHERAPY	2017
LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE	HAEMATOLOGICA	2017
How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes	EXPERT REVIEW OF HEMATOLOGY	2017
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study	BRITISH JOURNAL OF HAEMATOLOGY	2017